Taro Pharmaceutical Indus Q4 Adj EPS $0.43 Beats $0.31 Estimate, Sales $164.941M Beat $156.062M Estimate
Taro Pharmaceutical Indus Q4 Adj EPS $0.43 Beats $0.31 Estimate, Sales $164.941M Beat $156.062M Estimate
太郎製藥工業第四季度調整後每股收益0.43美元超過0.31美元的預期，1.649.41億美元的銷售額超過1.5662億美元的預期
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.31 by 38.71 percent. The company reported quarterly sales of $164.941 million which beat the analyst consensus estimate of $156.062 million by 5.69 percent. This is a 12.52 percent increase over sales of $146.587 million the same period last year.
太郎製藥工業公司（紐約證券交易所代碼：TARO）公佈的季度收益爲每股0.43美元，比分析師普遍預期的0.31美元高出38.71％。該公司公佈的季度銷售額爲1.64941億美元，比分析師普遍預期的1.56062億美元高出5.69％。這比去年同期的1.46587億美元的銷售額增長了12.52％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。